Abstract
Cytokine-induced killer (CIK) cells prossess phenotypic and functional hallmarks of both T cells and natural killer (NK) cells. The easy availability, high proliferation rate and widely major histocompatibility complex (MHC)-unrestricted antitumor activity of CIK cells contribute to their particularly advantageous profile, making them an attractive approach for adoptive immunotherapy. Initial clinical experiences demonstrated the efficacy of CIK cells immunotherapy in cancer patients. Likewise, the clinical application of CIK cells in combination with standard therapeutic procedures revealed synergistic antitumor effects. CIK cells demonstrated a crucial impact on the treatment of patients with hematological malignancies, as evidenced by complete remission (CR), prolonged survival durations and improved quality of life. This article reviews literatures on progress of CIK cells in treatment of hematological malignancies. Key words: Cytokine-induced killer cells; Clinical trials; Interleukin-2; Immunotherapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
